RxDoctor Payments DataLook up a doctor →

Michael Gold, MD

Dermatology · Nashville, TNNPI 1073549176

Payments from drug & device makers

$5,462,887in general payments, 2019–2025

Across 1,598 payments — averaging $3418.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2.8M
  • Merz North America, Inc.$739K
  • UCB SA$598K
  • Endo Pharmaceuticals Inc.$479K
  • Bausch Health US, LLC$205K
  • Aclaris Therapeutics, Inc.$108K
  • plus $575K from 54 others
$28,320in research payments, 2019–2025

Across 9 payments — averaging $3146.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$27K
  • AbbVie$1K
  • Biofrontera Inc.$63

What the payments were for

  • Consulting fees$343,93946%
  • Speaking & faculty fees$118,09716%
  • Grants$249,75033%
  • Travel & lodging$6,8171%
  • Food & beverage$28,1974%
  • Education$1,4060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)409$2,759,005
Merz North America, Inc.89$739,260
UCB SA50$597,729
Endo Pharmaceuticals Inc.39$478,578
Bausch Health US, LLC33$205,478
Aclaris Therapeutics, Inc.35$108,046
Journey Medical Corporation9$79,231
Solta Medical, A Division Of Bausch Health US, LLC27$59,055
Janssen Research & Development, LLC15$47,550
Galderma Laboratories, L.p.47$46,865
Mindera Corp3$34,563
Incyte Corporation47$33,911
Musculoskeletal Transplant Foundation Inc.11$23,864
Takeda Pharmaceuticals U.S.A., Inc.6$17,710
Strata Skin Sciences, Inc.48$15,752
Zerigo Health, Inc.5$15,000
Taro Pharmaceuticals USA, Inc.5$13,315
VYNE Pharmaceuticals Inc.16$13,166
Dermira, Inc.18$13,152
Sun Pharmaceutical Industries Inc.38$11,851
Amgen20$11,585
Almirall LLC22$11,537
LEO Pharma Inc.27$11,031
Lumenis, Inc3$10,500
Lumenis BE Inc3$10,400
Botanix SB Inc12$9,272
Kadmon Corporation LLC3$9,093
Galderma Research & Development, LLC2$8,866
EPI Health, LLC10$8,085
Ortho Dermatologics, A Division Of Bausch Health US, LLC39$7,922
Sensus Healthcare, Inc.1$7,500
UCB, Inc.54$6,658
Lumenis BE (hk) Limited2$5,797
Pfizer49$4,560
IBSA Institut Biochimique SA1$4,000
Janssen Scientific Affairs, LLC13$3,260
LEO Pharma AS1$2,588
Boehringer Ingelheim6$2,055
Novartis94$2,009
Biofrontera Inc.4$1,617
Lumenis (australia) PTY. LTD.1$1,500
Pierre Fabre Pharmaceuticals, Inc.1$1,500
LNHC, Inc4$1,322
Lilly USA, LLC22$1,194
Sanofi35$1,018
E.r. Squibb & Sons, L.L.C.50$904
Johnson & Johnson56$883
Regeneron3$578
Regeneron Healthcare Solutions, Inc.21$551
Dermavant Sciences, Inc.26$525
Arcutis Biotherapeutics, Inc.14$507
Organon8$189
Mayne Pharma Commercial LLC12$178
Convatec Inc.4$97
Arteriocyte Medical Systems, Inc.1$82
Bristol Myers Squibb1$74
Genentech USA, Inc.3$70
Organogenesis Inc.4$69
Paratek Pharmaceuticals, Inc.3$58
Revance Therapeutics, Inc.1$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,462,887 in reported general payments places this provider in the 95th percentile of 209 dermatology providers in Tennessee.

See all dermatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$196,612
Medicare patients
310
Services billed
4,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa31$624,627
Cosentyx Unoready PenSecukinumab39$421,270
Humira(Cf) PenAdalimumab29$327,139
Dupixent PenDupilumab72$269,419
Humira(Cf)Adalimumab14$189,957
ErivedgeVismodegib11$163,888
Cosentyx Sensoready (2 Pens)Secukinumab21$145,864
Dupixent SyringeDupilumab27$118,647
Humira PenAdalimumab12$77,754
OlumiantBaricitinib11$58,680
OpzeluraRuxolitinib Phosphate12$37,187
XolairOmalizumab11$33,037
Clobetasol Propionate180$7,271
Fluocinonide127$4,827
CiclopiroxCiclopirox Olamine72$4,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$2,759,005$189,95714 claims
Genentech USA, Inc.Erivedge$70$163,88811 claims
Lilly USA, LLCOlumiant$1,194$58,68011 claims
Incyte CorporationOpzelura$33,911$37,18712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 209 dermatology providers in Tennessee.

Other dermatology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →